




版權說明:本文檔由用戶提供并上傳,收益歸屬內容提供方,若內容存在侵權,請進行舉報或認領
文檔簡介
1、 附錄五:肝癌臨床分期及治療路線圖附錄六:原發性肝癌診療規范(2017年版)編寫專家委員會名譽主任委員:吳孟超湯釗猷劉允怡陳孝平王學浩孫燕鄭樹森主任委員:樊嘉副主任委員:秦叔逵沈鋒李強董家鴻周儉王偉林蔡建強滕皋軍外科學組組長:周儉;副組長:楊甲梅別平劉連新文天夫介入治療學組組長:王建華;副組長:韓國宏王茂強劉瑞寶陸驪工內科及局部治療組組長:秦叔逵;副組長:任正剛陳敏山曾昭沖梁萍影像學組組長:曾蒙蘇;副組長:梁長虹陳敏嚴福華王文平病理學組組長:叢文銘;副組長:紀元委員(按姓氏拼音排序):成文武戴朝六莢衛東李亞明李曄雄梁軍劉天舒呂國悅毛一雷任偉新石洪成孫惠川王文濤王曉穎邢寶才徐建明楊建勇楊業發葉勝
2、龍尹震宇張博恒張水軍周偉平朱繼業秘書長:孫惠川王征秘書:劉嶸史穎弘肖永勝代智七、參考文獻:1.TorreLA,BrayF,SiegelRL,FerlayJ,Lortet-TieulentJ,JemalA.Globalcancerstatistics,2012.CACancerJClin2015;65:87-108.ChenW,ZhengR,BaadePD,etal.CancerstatisticsinChina,2015.CACancerJClin2016;66:115-32.ZhangBH,YangBH,TangZY.Randomizedcontrolledtrialofscreeningf
3、orhepatocellularcarcinoma.JCancerResClinOncol2004;130:417-22.ZengMS,YeHY,GuoL,etal.Gd-EOB-DTPA-enhancedmagneticresonanceimagingforfocalliverlesionsinChinesepatients:amulticenter,open-label,phaseIIIstudy.HepatobiliaryPancreatDisInt2013;12:607-16.LeeYJ,LeeJM,LeeJS,etal.Hepatocellularcarcinoma:diagnost
4、icperformanceofmultidetectorCTandMRimaging-asystematicreviewandmeta-analysis.Radiology2015;275:97-109.IchikawaT,SaitoK,YoshiokaN,etal.Detectionandcharacterizationoffocalliverlesions:aJapanesephaseIII,multicentercomparisonbetweengadoxeticaciddisodium-enhancedmagneticresonanceimagingandcontrast-enhanc
5、edcomputedtomographypredominantlyinpatientswithhepatocellularcarcinomaandchronicliverdisease.InvestRadiol2010;45:133-41.丁鶯,陳財忠,饒圣祥,曾蒙蘇.Gd+-EOB-DTPA與Gd+-DTPA增強磁共振檢查肝細胞癌的對照研究中華普通外科雜志2013;28:682-5.YooSH,ChoiJY,JangJW,etal.Gd-EOB-DTPA-enhancedMRIisbetterthanMDCTindecisionmakingofcurativetreatmentforhepa
6、tocellularcarcinoma.AnnSurgOncol2013;20:2893-900.ChenCZ,RaoSX,DingY,etal.Hepatocellularcarcinoma20mmorsmallerincirrhosispatients:earlymagneticresonanceenhancementbygadoxeticacidcomparedwithgadopentetatedimeglumine.HepatolInt2014;8:104-11.ChenBB,MurakamiT,ShihTT,etal.Novelimagingdiagnosisforhepatocel
7、lularcarcinoma:consensusfromthe5thAsia-PacificPrimaryLiverCancerExpertMeeting(APPLE2014).LiverCancer2015;4:215-27.MerkleEM,ZechCJ,BartolozziC,etal.Consensusreportfromthe7thInternationalForumforLiverMagneticResonanceImaging.EurRadiol2016;26:674-82.ParkJW,KimJH,KimSK,etal.Aprospectiveevaluationof18F-F
8、DGand11C-acetatePET/CTfordetectionofprimaryandmetastatichepatocellularcarcinoma.JNuclMed2008;49:1912-21.LinCY,ChenJH,LiangJA,LinCC,JengLB,KaoCH.18F-FDGPETorPET/CTfordetectingextrahepaticmetastasesorrecurrenthepatocellularcarcinoma:asystematicreviewandmeta-analysis.EurJRadiol2012;81:2417-22.Boellaard
9、R,Delgado-BoltonR,OyenWJ,etal.FDGPET/CT:EANMprocedureguidelinesfortumourimaging:version2.0.EurJNuclMedMolImaging2015;42:328-54.BoellaardR,ODohertyMJ,WeberWA,etal.FDGPETandPET/CT:EANMprocedureguidelinesfortumourPETimaging:version1.0.EurJNuclMedMolImaging2010;37:181-200.WahlRL,JaceneH,KasamonY,LodgeMA
10、.FromRECISTtoPERCIST:EvolvingConsiderationsforPETresponsecriteriainsolidtumors.JNuclMed2009;50Suppl1:122S-50S.ChalianH,ToreHG,HorowitzJM,SalemR,MillerFH,YaghmaiV.Radiologicassessmentofresponsetotherapy:comparisonofRECISTVersions1.1and1.0.Radiographics2011;31:2093-105.FerdaJ,FerdovaE,BaxaJ,etal.Thero
11、leof18F-FDGaccumulationandarterialenhancementasbiomarkersintheassessmentoftyping,gradingandstagingofhepatocellularcarcinomausing18F-FDG-PET/CTwithintegrateddual-phaseCTangiography.AnticancerRes2015;35:2241-6.LeeJW,OhJK,ChungYA,etal.PrognosticSignificanceof18F-FDGUptakeinHepatocellularCarcinomaTreate
12、dwithTransarterialChemoembolizationorConcurrentChemoradiotherapy:AMulticenterRetrospectiveCohortStudy.JNuclMed2016;57:509-16.HyunSH,EoJS,LeeJW,etal.Prognosticvalueof18F-fluorodeoxyglucosepositronemissiontomography/computedtomographyinpatientswithBarcelonaClinicLiverCancerstages0andAhepatocellularcar
13、cinomas:amulticenterretrospectivecohortstudy.EurJNuclMedMolImaging2016.BertagnaF,BertoliM,BosioG,etal.DiagnosticroleofradiolabelledcholinePETorPET/CTinhepatocellularcarcinoma:asystematicreviewandmeta-analysis.HepatolInt2014;8:493-500.CheungTT,HoCL,LoCM,etal.11C-acetateand18F-FDGPET/CTforclinicalstag
14、ingandselectionofpatientswithhepatocellularcarcinomaforlivertransplantationonthebasisofMilancriteria:surgeonsperspective.JNuclMed2013;54:192-200.ZhangY,ShiH,LiB,CaiL,GuY,XiuY.TheaddedvalueofSPECT/spiralCTinpatientswithequivocalbonymetastasisfromhepatocellularcarcinoma.Nuklearmedizin2015;54:255-61.Fo
15、rnerA,VilanaR,AyusoC,etal.Diagnosisofhepaticnodules20mmorsmallerincirrhosis:Prospectivevalidationofthenoninvasivediagnosticcriteriaforhepatocellularcarcinoma.Hepatology2008;47:97-104.25.陳孝平.肝惡性腫瘤.In:陳孝平,ed.外科學.第2版ed.北京:人民衛生出版社;2010:620.26.WestraWH,HrubanRH,PhelpsTH,IsacsonC.SurgicalPathologyDissecti
16、on:AnIllustratedGuide.NewYork:Springer;2003.27.NaraS,ShimadaK,SakamotoY,etal.Prognosticimpactofmarginalresectionforpatientswithsolitaryhepatocellularcarcinoma:evidencefrom570hepatectomies.Surgery2012;151:526-36.28.叢文銘.肝細胞性惡性腫瘤.In:叢文銘,ed.肝膽腫瘤外科病理學.1ed.北京:人民衛生出版社;2015:276-320.29.ScheuerPJ.Classificati
17、onofchronicviralhepatitis:aneedforreassessment.JHepatol1991;13:372-4.30.病毒性肝炎防治方案.中華傳染病雜志2001;19:56-62.31.GuidelinesforthePrevention,CareandTreatmentofPersonswithChronicHepatitisBInfection.Geneva2015.32.Rodriguez-PeralvarezM,LuongTV,AndreanaL,MeyerT,DhillonAP,BurroughsAK.Asystematicreviewofmicrovasc
18、ularinvasioninhepatocellularcarcinoma:diagnosticandprognosticvariability.AnnSurgOncol2013;20:325-39.33.中國抗癌協會肝癌專業委員會,中華醫學會肝病學分會肝癌學組,中國抗癌協會病理專業委員會,etal.原發性肝癌規范化病理診斷指南(2015年版).中華肝膽外科雜志2015;21:145-51.EguchiS,TakatsukiM,HidakaM,etal.Predictorforhistologicalmicrovascularinvasionofhepatocellularcarcinoma:
19、alessonfrom229consecutivecasesofcurativeliverresection.WorldJSurg2010;34:1034-8.FujitaN,AishimaS,IguchiT,etal.Histologicclassificationofmicroscopicportalvenousinvasiontopredictprognosisinhepatocellularcarcinoma.HumPathol2011;42:1531-8.IguchiT,ShirabeK,AishimaS,etal.NewPathologicStratificationofMicro
20、vascularInvasioninHepatocellularCarcinoma:PredictingPrognosisAfterLiving-donorLiverTransplantation.Transplantation2015;99:1236-42.ImamuraH,SeyamaY,KokudoN,etal.Onethousandfifty-sixhepatectomieswithoutmortalityin8years.ArchSurg2003;138:1198-206;discussion206.KubotaK,MakuuchiM,KusakaK,etal.Measurement
21、oflivervolumeandhepaticfunctionalreserveasaguidetodecision-makinginresectionalsurgeryforhepatictumors.Hepatology1997;26:1176-81.BruixJ,CastellsA,BoschJ,etal.Surgicalresectionofhepatocellularcarcinomaincirrhoticpatients:prognosticvalueofpreoperativeportalpressure.Gastroenterology1996;111:1018-22.Cesc
22、onM,ColecchiaA,CucchettiA,etal.ValueoftransientelastographymeasuredwithFibroScaninpredictingtheoutcomeofhepaticresectionforhepatocellularcarcinoma.AnnSurg2012;256:706-12;discussion12-3.ChenMS,LiJQ,ZhengY,etal.Aprospectiverandomizedtrialcomparingpercutaneouslocalablativetherapyandpartialhepatectomyfo
23、rsmallhepatocellularcarcinoma.AnnSurg2006;243:321-8.LiuPH,HsuCY,HsiaCY,etal.SurgicalResectionVersusRadiofrequencyAblationforSingleHepatocellularCarcinoma/=5cm)HepatocellularCarcinoma:MicrowaveAblationImmediatelyFollowedbyTransarterialChemoembolization.JVascIntervRadiol2016.ZengZC,TangZY,FanJ,etal.Ac
24、omparisonofchemoembolizationcombinationwithandwithoutradiotherapyforunresectablehepatocellularcarcinoma.CancerJ2004;10:307-16.MengMB,CuiYL,LuY,etal.Transcatheterarterialchemoembolizationincombinationwithradiotherapyforunresectablehepatocellularcarcinoma:asystematicreviewandmeta-analysis.RadiotherOnc
25、ol2009;92:184-94.ZengZC,FanJ,TangZY,etal.Acomparisonoftreatmentcombinationswithandwithoutradiotherapyforhepatocellularcarcinomawithportalveinand/orinferiorvenacavatumorthrombus.IntJRadiatOncolBiolPhys2005;61:432-43.ZengZC,TangZY,FanJ,etal.Considerationofroleofradiotherapyforlymphnodemetastasesinpati
26、entswithHCC:retrospectiveanalysisforprognosticfactorsfrom125patients.IntJRadiatOncolBiolPhys2005;63:1067-76.ZhouLY,ZengZC,FanJ,etal.Radiotherapytreatmentofadrenalglandmetastasesfromhepatocellularcarcinoma:clinicalfeaturesandprognosticfactors.BmcCancer2014;14:878-87.HeJ,ZengZC,TangZY,etal.Clinicalfea
27、turesandprognosticfactorsinpatientswithbonemetastasesfromhepatocellularcarcinomareceivingexternalbeamradiotherapy.Cancer2009;115:2710-20.WangWH,WangZ,WuJX,etal.SurvivalbenefitwithIMRTfollowingnarrow-marginhepatectomyinpatientswithhepatocellularcarcinomaclosetomajorvessels.LiverInt2015;35:2603-10.Wan
28、gMH,JiY,ZengZC,etal.Impactfactorsformicroinvasioninpatientswithhepatocellularcarcinoma:possibleapplicationtothedefinitionofclinicaltumorvolume.IntJRadiatOncolBiolPhys2010;76:467-76.101.曾昭沖.肝細胞癌的立體定向放射治療.中華腫瘤雜志2015:650-2,3.DawsonLA,NormolleD,BalterJM,McGinnCJ,LawrenceTS,TenHakenRK.Analysisofradiation
29、-inducedliverdiseaseusingtheLymanNTCPmodel.IntJRadiatOncolBiolPhys2002;53:810-21.LiangSX,ZhuXD,XuZY,etal.Radiation-inducedliverdiseaseinthree-dimensionalconformalradiationtherapyforprimarylivercarcinoma:theriskfactorsandhepaticradiationtolerance.IntJRadiatOncolBiolPhys2006;65:426-34.ChonYE,SeongJ,Ki
30、mBK,etal.Gastroduodenalcomplicationsafterconcurrentchemoradiationtherapyinpatientswithhepatocellularcarcinoma:endoscopicfindingsandriskfactors.IntJRadiatOncolBiolPhys2011;81:1343-51.HouJZ,ZengZC,WangBL,YangP,ZhangJY,MoHF.Highdoseradiotherapywithimage-guidedhypo-IMRTforhepatocellularcarcinomawithport
31、alveinand/orinferiorvenacavatumorthrombiismorefeasibleandefficaciousthanconventional3D-CRT.JpnJClinOncol2016;46:357-62.HuY,ZhouYK,ChenYX,ShiSM,ZengZC.4D-CTscansrevealreducedmagnitudeofrespiratorylivermotionachievedbydifferentabdominalcompressionplatepositionsinpatientswithintrahepatictumorsundergoin
32、ghelicaltomotherapy.MedPhys2016;43:4335.LauWY,TeohYL,WinKM,etal.Currentroleofselectiveinternalradiationwithyttrium-90inlivertumors.FutureOncol2016;12:1193-204.XuJ,ShenZY,ChenXG,etal.ArandomizedcontrolledtrialofLicartinforpreventinghepatomarecurrenceafterlivertransplantation.Hepatology2007;45:269-76.
33、RaoulJL,GuyaderD,BretagneJF,etal.Randomizedcontrolledtrialforhepatocellularcarcinomawithportalveinthrombosis:intra-arterialiodine-131-iodizedoilversusmedicalsupport.JNuclMed1994;35:1782-7.LlovetJM,RicciS,MazzaferroV,etal.Sorafenibinadvancedhepatocellularcarcinoma.NEnglJMed2008;359:378-90.PressianiT,
34、BoniC,RimassaL,etal.SorafenibinpatientswithChild-PughclassAandBadvancedhepatocellularcarcinoma:aprospectivefeasibilityanalysis.AnnOncol2013;24:406-11.QinS,BaiY,LimHY,etal.Randomized,multicenter,open-labelstudyofoxaliplatinplusfluorouracil/leucovorinversusdoxorubicinaspalliativechemotherapyinpatientswithadvancedhepatocellularcarcinomafromAsia.JClinOncol2013;31:3501-8.LeeJH,LeeJH,LimYS,et
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯系上傳者。文件的所有權益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網頁內容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
- 4. 未經權益所有人同意不得將文件中的內容挪作商業或盈利用途。
- 5. 人人文庫網僅提供信息存儲空間,僅對用戶上傳內容的表現方式做保護處理,對用戶上傳分享的文檔內容本身不做任何修改或編輯,并不能對任何下載內容負責。
- 6. 下載文件中如有侵權或不適當內容,請與我們聯系,我們立即糾正。
- 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- Fibrostatin-B-生命科學試劑-MCE
- 2025廚房設備租賃合同范本
- 語文《羅布泊消逝的仙湖》教學設計
- 新人教九上《2我們周圍的空氣》復習教學設計
- (高清版)DB13∕T 5127.11-2019 植入性醫療器械高分子材料浸提液中有毒有害物質的測定 第11部分:戊二醛遷移量高效液相色譜法
- (高清版)DB13∕T 2986-2019 鹽堿地蒲公英栽培技術規程
- 2025年安徽省滁州市滁州經濟技術開發區中考三模語文試題
- 現代心理學人格發展題庫
- 學歷認證書教育背景證明(7篇)
- 汽車發動機技術故障診斷練習題集
- 初始污染菌檢測原始記錄
- 安全標準化現場評審所需資料清單(共14頁)
- 罪犯教育-身份意識和改造心態教育
- 胃腸減壓技術操作流程.
- 鏈家房屋買賣合同范本(共10篇)
- 工序能耗計算方法及等級指標
- 鋸齒形板式熱水冷卻器的設計3.
- 藥店組織機構圖及部門設置說明
- DSP課程設計--基于IIR的語音信號濾波
- 危大工程驗收表-
- 葉輪動平衡試驗報告A
評論
0/150
提交評論